Spurred by a Wall Street analyst’s purchase...

Spurred by a Wall Street analyst’s purchase recommendation, investors continued frenzied buying of ICN Pharmaceuticals Inc. stock Thursday, putting the Costa Mesa drug maker on the New York Stock Exchange’s most-active list for the second day in a row. As the third most active issue Thursday, ICN gained $2.25 to close at $24.25 a share with 1.45 million shares traded. The stock had gained $3.125 Wednesday. On Wednesday, Ronald Nordmann, of PaineWebber Mitchell Hutchins, issued a bullish report that said the company’s anti-viral drug, Virazole, eventually may be approved for use against influenza. The drug also is being tested as a potential medication for AIDS.